|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.99/-2.06
|
Enterprise Value
499.73M
|
Balance Sheet |
Book Value Per Share
3.20
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
3.53M
|
Operating Revenue Per Share
0.62
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/12/24 13:25 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S. |